Author:
Dellamonica P.,Di Perri G.,Garraffo R.
Reference67 articles.
1. Wilkin A, Pozniak A, Morales-Ramirez J, et al. Long-term efficacy, safety and tolerability of TMC278 in HIV-1-infected antiretroviral-naïve patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2011 [Epub ahead of print].
2. Nevirapine and cardiovascular risk;Parienti;Med Mal Infect,2010
3. Mechanisms of inhibition of HIV replication by non-nucleosidereverse transcriptase inhibitors;Sluis-Cremer;Virus Res,2008
4. Pharmacokinetic parameters of Nevirapone and Efavirens in relation to antiretroviral efficacy;Van Leth;AIDS Res Hum Retroviruses,2006
5. Gathe J, Bogner J, Santiago S, et al. Comparison of 48-week efficacy and safety of 400mg QD nevirapine extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE). In: XVIII International AIDS Conference (IAS); July 18–23, 2010; Vienna, Austria: Abstract THLBB202.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献